Our results also showed a protective effect for IGF-I on liver steatosis, as IGF-I improved protein expression of FXR, SRECBP-1, and FAS that are involved in NAFLD features. This evidence concerns the gene FAS and metabolic dysfunction-associated steatotic liver disease.